5‐Day <b>H. pylori</b> eradication

Treiber,; Ammon, Laura; Klotz,

doi:10.1046/j.1365-2036.1999.0612c.x

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previous studies have indicated that age might have some impact on the clinical outcome, the influence of this variable on the disposition of the involved drugs within a clinical H. pylori eradication study was evaluated 12 –14 . Changes in pharmacokinetics might, at least to some extent, account for the higher H. pylori eradication rates seen in elderly patients.…”

Section: Discussionmentioning

confidence: 99%

“…Recently we tested a new short‐term (5 days) quadruple therapy (proton pump inhibitor + amoxycillin + clarithromycin + metronidazole) which represents a cost saving, effective and safe regimen 11 . Based on experience with earlier studies it was noted that the age of the patients had some influence on the clinical outcome: in elderly subjects (> 55 years) higher H. pylori eradication rates could be observed 12 –14 . It remained to be elucidated whether an age‐dependent disposition of the involved drugs contributed to this phenomenon.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori

Ammon

Treiber

Kees

et al. 2000

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori

Ammon

Treiber

Kees

et al. 2000

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Pharmacokinetic Considerations in the Eradication of Helicobacter Pylori

Klotz

2000

Clinical Pharmacokinetics

103

View full text Add to dashboard Cite

As Helicobacter pylori plays an important role in the aetiopathogenesis of peptic ulcer, therapeutic strategies aimed at maintaining long term remission have shifted from the control of intragastric pH to targeting H. pylori. According to recent international guidelines the clinical goals--rapid ulcer healing and prevention of relapse--can be best accomplished by combination therapy consisting of an antisecretory drug (proton pump inhibitor or ranitidine) and 2 antimicrobial agents (preferable amoxicillin, clarithromycin or metronidazole). When applying such multidrug regimens, possible synergy between the agents suggests that pharmacokinetic considerations might help to improve H. pylori eradication rates, which should be above 85 to 90% on an intention-to-treat basis. The present review summarises the pharmacokinetic properties and interaction potential of all drugs presently used in the various H. pylori eradication regimens, with emphasis on particular patient populations such as the elderly and those with renal impairment. The drugs considered are omeprazole, lansoprazole, pantoprazole, rabeprazole, ranitidine and ranitidine bismutrex, bismuth salts, amoxicillin, clarithromycin, azithromycin, roxithromycin, metronidazole, tinidazole and tetracycline. When addressing the clinically important questions of the efficacy, safety and costs of the recommended regimens, the impact of drug disposition on H. pylori eradication should not be neglected.

show abstract

5‐Day H. pylori eradication

Cited by 2 publications

References 4 publications

Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori

Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori

Pharmacokinetic Considerations in the Eradication of Helicobacter Pylori

Contact Info

Product

Resources

About